Journal of
eISSN: 2376-0060
Submit manuscript...
Editorial Volume 9 Issue 2
COVID-19-Vaccination-induced-airway-immune responses in patients with chronic obstructive pulmonary disease and healthy individuals
Attapon Cheepsattayakorn,1,2 
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
Ruangrong Cheepsattayakorn,3 Porntep Siriwanarangsun1
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
1Faculty of Medicine, Western University, Pathumtani Province, Thailand
210th Zonal Tuberculosis and Chest Disease Center, Thailand
3Department of Pathology,Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Correspondence: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100 Thailand
Received: June 30, 2022 | Published: July 4, 2022
Citation: Cheepsattayakorn A, Cheepsattayakorn R, Siriwanarangsun P. COVID-19-Vaccination-induced-airwayimmune responses in patients with chronic obstructive pulmonary disease and healthy individuals. J Lung Pulm Respir Res. 2022;9(2):44. DOI: 10.15406/jlprr.2022.09.00278
Editorial
To our knowledge, the impact of SARS-CoV-2 (COVID-19) infection among persons with chronic obstructive pulmonary disease (COPD) and other vulnerable persons remains unclear.1 A recent study among 27 COVID-19 vaccinated individuals (11 COPD subjects (either GOLD grade 2 (n=9) or grade 3 (n=2) with 10 being ex-smokers (All subjects were aged >40years) and 16 healthy control subjects (All subjects were aged >40years), 43 pre-COVID-19-vaccination subjects (All were aged > 40years), and 9 healthy control subjects (All subjects were aged >40years) with a history of SARS-CoV-2 (COVID-19) infection, at >2 weeks of COVID-19 vaccinated subjects’ specimen donation (collection) after completing two doses of either Comirnaty (Pfizer; 6 COPD patients and 7 healthy control subjects) or Vaxzervria (Oxford-AstraZeneca; 5 COPD patients and 9 healthy control subjects) revealed that anti-spike IgG antibody, but not IgA levels were higher in airways (sputum or nasal specimen collection) post-COVID-19 vaccination.2 Similar responses of anti-spike IgG antibody in patients with COPD and healthy control subjects were also demonstrated.2 Comirnaty vaccine is known to produce higher systemic anti-spike immunoglobulins, in comparison to Vaxzervria vaccine.3
Conclusion
Early nasal anti-IgA antibody responses are COVID-19 vaccine dependent, whereas COVID-19-vaccine-induced mucosal anti-IgG antibody responses persist for longer than anti-IgA antibody responses.
Acknowledgments
None.
Conflicts of interest
None.
Funding
None.
References
- Montiel-Lopez F, Miranda-Ma´rquez MC, Cassou-Marti´nez M, et al. Efficacy of Sputnik vaccine against fatality outcomes in a COPD patient with COVID-19.Am J Biomed Sci & Res. 2021;12(6).
- Southworth T, Jackson N, Singh D, et al. Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects. Ear Respir J. 2022.
- Kang YM, Minn D, lim J, et al. Comparison of antibody response elicited by ChAdOx1 and BNT162b2 COVID-19 vaccine. J Korean Med Sci. 2021;36(46):e311.
©2022 Cheepsattayakorn, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.